Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales ...

Theriva received a $300,000 upfront payment at signing and is eligible for up to $38M in development, regulatory, and sales milestones along with tiered single-digit royalties on net product sales - - ...

Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of ...

Bacteria have evolved to adapt to all of Earth's most extreme conditions, from scorching heat to temperatures well below zero ...

A 91-year-old man with a history of bladder carcinoma and left total knee arthroplasty was evaluated because of left knee pain. A culture of synovial fluid showed no growth. A diagnosis was made.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...

Antibiotic resistant infections are becoming increasingly common and are expected to become the leading cause of death worldwide by 2050. This alarming scenario could, however, be mitigated by the ...

Bacteria have evolved to adapt to all of Earth's most extreme conditions, from scorching heat to temperatures well below zero ...

This narrative review in the British Journal of Biomedical Science examines emerging and recently approved therapeutic strategies to combat antimicrobial resistance, spanning new antibiotics, ...